Inovio Pharmaceuticals, Inc. · NASDAQ:INO
Inovio Pharmaceuticals — Q3 2025 Earnings Presentation
19 slides from Inovio Pharmaceuticals's earnings presentation, Nov 10, 2025
Slide 1: Third Quarter 2025 Financial Results
Third Quarter 2025 Financial Results November 2025
Slide 2: Agenda
Agenda Introduction Jennie Willson, Director, Communications CEO Perspective & Corporate Progress Jacqueline Shea, PhD, President & Chief Executive Officer INO-3107 Update Michael Sumner, MBBS, MBA, Chief Medical Officer Steve Egge, MBA, Chief Commercial Officer Financial Results Peter Kies, Chief F
Slide 3: Forward-Looking Statements
Forward-Looking Statements This presentation includes statements that are, or may be deemed, “forward-looking statements,” within the meaning of Section 27A of the Securities Act of 1933, as amended. All statements, other than statements of historical facts, included in this presentation regarding o
Slide 4: Update: 2025 Strategic Priorities
Update: BLA for INO-3107 2025 • Completed rolling BLA submission, seeking accelerated approval Strategic • File acceptance expected EOY Priorities • Requested Priority Review; if granted, potential PDUFA in mid-2026 Commercialization Preparations • Ongoing market research with physicians, patients a
Slide 5: INO-3107 for Recurrent Respiratory Papillomatosis (RRP)
LEAD CANDIDATE: INO-3107 for Recurrent Respiratory Papillomatosis (RRP) Potentially transformational therapy under accelerated approval pathway
Slide 6: Regulatory Update: Next Milestones
INO-3107 Regulatory Update: Next Milestones • Expect BLA file acceptance by EOY; If Priority Review granted, potential PDUFA date mid-2026 • Submit revised IND to initiate confirmatory trial - Have submitted a request for a Type D meeting with FDA to discuss options for trial design • Begin enrollin
Slide 7: Foundational Strengths of RRP Program
INO-3107 Foundational Strengths of RRP Program Designed with every surgery—and every patient—in mind Unmet • Debilitating rare disease caused primarily by HPV-6 & HPV-11, characterized by small, Medical Need wart-like growths in respiratory tract • Current standard of care (repeat surgeries) does no
Slide 8: For RRP Patients, Every Surgery Matters
INO-3107 For RRP Patients, Every Surgery Matters MEAN SURGERIES PER YEAR PRE-TREATMENT Year -1 (N=32) 4.1 Year 1 (N=32) 1.7 ↓78% (Year -1 to Year 2) ↓47% (Year 1 to Year 2) POST-TREATMENT Year 2 (N=28) 0.9 Year 3* (N=28) 0.8 *Complete data not available for all patients; median Year 3 available data
Slide 9: Surgery Should Be a Last Resort, Not a First-line Treatment
INO-3107 Surgery Should Be a Last Resort, Not a First-line Treatment INO-3107: RRP-001 PHASE 1/2 OPEN-LABEL STUDY AT 8 SITES PATIENTS WITH 2+ SURGERIES IN YR PRIOR TO TREATMENT Baseline: DAY 0 WEEK 52 - Initial Surgery: up to 14 days before first dose Patients Enrolled 4 Doses of INO-3107 Completed
Slide 10: Market Research Continues to Support Preferred Product Profile
INO-3107 Market Research Continues to Support Preferred Product Profile EFFICACY TOLERABILITY SIMPLICITY Improving response over time Well tolerated Patient-centric treatment • Overall Response Rate (50% to • 41% (13/32) reported treatment- • Office-based administration that 100% reduction in surger
Slide 11: Advancing Launch Preparations
INO-3107 Advancing Launch Preparations Key Market Research and Planning: • Continued critical research with payers • Developed initial pricing strategy with price optimization research ongoing • Completed targeting, segmentation and product positioning work - supporting positive differentiation Oper
Slide 12: Financial Update
2Q25 Financial Update
Slide 13: Achieving Strategic Goals While Reducing Costs
Achieving Strategic Goals While Reducing Costs THREE MONTHS NINE MONTHS ENDED SEPT 30 (UNAUDITED) ENDED SEPT 30 (UNAUDITED) % % 2025 2024 CHANGE 2025 2024 CHANGE Operating expenses $21.2 $27.3 (22%) $69.4 $92.1 (25%) Net loss* ($45.5) ($25.2) 81% $(88.7) ($87.9) 1% Net loss per share ($0.87) ($.89)
Slide 14: Pipeline Update
Pipeline Update
Slide 15: INOVIO Pipeline
INOVIO Pipeline PRECLINICAL PHASE 1 PHASE 2 PHASE 3 REGISTRATION DMAbs INO-5401 VGX-3100 INO-3107 * Various Targets BRCA 1/2 Mutation Anal Dysplasia RRP DPROTs INO-4201 INO-3112 Various targets Ebola Booster Head & Neck Cancer DLNPs INO-6172 INO-5401 Various targets HIV Glioblastoma INO-6160 HIV DMA
Slide 16: Q&A
Q&A
Slide 17: Upcoming Key Catalysts
Upcoming Key Catalysts INO-3107 Commercialization Pipeline • File acceptance by EOY, • Be ready to launch quickly Next Gen Candidates potential PDUFA date in and efficiently if approved • Complete Phase 1 DMAb trial mid-2026 • Continue to build on • Identify partnership • Finalize confirmatory trial
Slide 18: Every patient deserves a therapy that works for them
“ Every patient deserves a therapy that works for them. I believe we are now one step closer to surgery being a last resort for the treatment of this disease.” Kim McClellan, President of the RRP Foundation, on the completed BLA submission for INO-3107 18
Slide 19: Contact: investor.relations@inovio.com
Contact: investor.relations@inovio.com
Inovio Pharmaceuticals — Q3 2025 Earnings Presentation on 6ix